The effectiveness of Sputnik Light against the Delta variant of the coronavirus is 70% in the three months after vaccination, according to the Russian Direct Investment Fund (RDIF) and the Gamaleya Center.
At a press conference, the developers of the vaccine released the results of the analysis carried out to determine the effectiveness of the same that has the first component of Sputnik V.
In addition to 70% effectiveness within three months of immunization, it was determined that in the age group less than 60 years, the effectiveness exceeded 75%.
According to the RDIF and the Gamaleya Center, “these indicators exceed those of many foreign two-component vaccines, which show a significant decrease in efficacy to less than 50% five months after vaccination.”
“The Sputnik Light vaccine is a good solution for countries with a low level of vaccination of the population, due to its one-component scheme, and it can also be used successfully as a booster injection to maintain the existing immunity in the population”, said Denis Logunov, deputy director of research at the NITsEM NF Gamaleya Center.
Meanwhile, Kirill Dmitriev, CEO of Russia’s Direct Investment Fund (RDIF), said: “Sputnik Light is safe and very effective both when used alone and in combination with other vaccines. Sputnik Light provides flexibility of regimens. immunization for the population both for the formation of primary immunity and for the effective revaccination of people previously vaccinated with vaccines from other manufacturers “.
During the conference it was also reported that the article with the results of the analysis has been sent to the portal of manuscripts of scientific articles in the field of medicine MedRxiv for publication in the course of this week.
Another of the data released is that the efficacy of Sputnik Light “as a booster injection for other vaccines will be close to the efficacy rates of Sputnik V against this variant: more than 83% against infection and more than 94% against hospitalization “.
The analysis was carried out by the NITsEM NF Gamaleya Center on the basis of data from 28 thousand people vaccinated once with Sputnik Light, compared to a control group of 5.6 million unvaccinated citizens. And it was reported that the study was carried out on the basis of July 2021 data, obtained in Moscow.
So far, the two-component Sputnik V vaccine is registered in 70 countries, and Sputnik Light has been approved in more than 15 countries and is in the process of registration in another 30. (NA)